Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VRTX

Vertex Pharmaceuticals, Inc

Dec 20 • 04:00PM ET

397.27

Dollar change +0.63
Percentage change 0.16	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB GILD AMGN REGN MRNA INCY ALNY NBIX EXEL

| Held by: VTI VOO QQQ VUG SPY IVV XLV IBB VHT QQQM

Scroll to Statements

Index	NDX, S&P 500	P/E	-	EPS (ttm)	-1.99	Insider Own	0.24%	Shs Outstand	257.74M	Perf Week	-14.33%
Market Cap	102.47B	Forward P/E	21.17	EPS next Y	18.77	Insider Trans	-10.13%	Shs Float	256.90M	Perf Month	-11.96%
Income	-479.80M	PEG	-	EPS next Q	4.05	Inst Own	92.75%	Short Float	1.43%	Perf Quarter	-13.64%
Sales	10.62B	P/S	9.65	EPS this Y	-96.45%	Inst Trans	-0.26%	Short Ratio	2.81	Perf Half Y	-16.36%
Book/sh	60.65	P/B	6.55	EPS next Y	3368.96%	ROA	-2.18%	Short Interest	3.67M	Perf Year	-0.74%
Cash/sh	25.33	P/C	15.68	EPS next 5Y	12.20%	ROE	-2.99%	52W Range	377.85 - 519.88	Perf YTD	-2.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.42%	ROI	-2.77%	52W High	-23.58%	Beta	0.40
Dividend TTM	-	Quick Ratio	2.20	Sales past 5Y	27.16%	Gross Margin	86.11%	52W Low	5.14%	ATR (14)	15.87
Dividend Ex-Date	-	Current Ratio	2.47	EPS Y/Y TTM	-113.76%	Oper. Margin	-2.90%	RSI (14)	24.09	Volatility	3.99% 2.54%
Employees	5400	Debt/Eq	0.11	Sales Y/Y TTM	10.96%	Profit Margin	-4.52%	Recom	1.89	Target Price	507.93
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	0.82%	Payout	0.00%	Rel Volume	4.64	Prev Close	396.64
Sales Surprise	3.22%	EPS Surprise	7.41%	Sales Q/Q	11.86%	Earnings	Nov 04 AMC	Avg Volume	1.31M	Price	397.27
SMA20	-13.06%	SMA50	-15.61%	SMA200	-13.19%	Trades		Volume	6,052,103	Change	0.16%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$600 → $535
Dec-19-24	Downgrade	Oppenheimer	Outperform → Perform
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$500 → $550
Nov-14-24	Initiated	Citigroup	Buy	$575
Oct-16-24	Initiated	Scotiabank	Sector Perform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-05-24	Downgrade	Barclays	Overweight → Equal Weight	$472 → $509
Jun-27-24	Initiated	Redburn Atlantic	Buy	$545
Apr-11-24	Upgrade	Evercore ISI	In-line → Outperform	$438
Feb-15-24	Initiated	Wolfe Research	Outperform	$515
Feb-06-24	Downgrade	Evercore ISI	Outperform → In-line	$436 → $438
Feb-02-24	Downgrade	Bernstein	Outperform → Mkt Perform
Jan-31-24	Downgrade	Robert W. Baird	Neutral → Underperform	$325
Jan-31-24	Downgrade	Maxim Group	Buy → Hold
Jan-24-24	Downgrade	Canaccord Genuity	Hold → Sell	$332 → $379
Dec-14-23	Reiterated	RBC Capital Mkts	Sector Perform	$347 → $379
May-30-23	Initiated	William Blair	Outperform	$382
May-04-23	Resumed	Piper Sandler	Overweight	$385
Mar-21-23	Initiated	Bernstein	Outperform	$344
Jan-18-23	Initiated	Canaccord Genuity	Hold	$311

Show Previous Ratings

Today 07:30AM	Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein (TipRanks)
06:48AM	3 Fantastic Stocks That Could Enjoy a Santa Claus Rally (Motley Fool)
04:05AM	My Top 10 Stocks to Buy for 2025 (Motley Fool)
Dec-20-24 06:16PM	Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock (Investor's Business Daily)
03:46PM	Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis (Business Wire)
03:35PM	Loading…
03:35PM	Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants (Business Wire)
10:38AM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
08:00AM	Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? (Investor's Business Daily)
Dec-19-24 07:45PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research) -11.37%
04:44PM	S&P 500 Gains and Losses Today: Darden Restaurants Stock Sizzles After Sales Beat (Investopedia)
04:19PM	Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug (Investor's Business Daily)
04:05PM	Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): I Think You Should Buy The Dip Here (Insider Monkey)
01:06PM	Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? (Benzinga)
12:01PM	Accenture, Robinhood and Coinbase, Vertex: Market Minute (Yahoo Finance Video)
10:43AM	Vertex Pain Drug Doesnt Beat Placebo. The Company Says It Still Sees Promise. (Barrons.com)
10:33AM	Loading…
10:33AM	Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic (GuruFocus.com)
10:20AM	Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results (Investopedia)
09:16AM	Heres Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3 (Insider Monkey)
08:53AM	Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain (Investor's Business Daily)
08:06AM	Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging. (Investor's Business Daily)
06:00AM	Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy (Business Wire)
04:20AM	2 Unstoppable Stocks to Buy and Hold for the Next Decade (Motley Fool)
Dec-18-24 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Dec-16-24 05:50PM	Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market Today (Zacks)
04:15AM	Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030 (Motley Fool)
Dec-15-24 06:07AM	3 Unstoppable Stocks to Buy Right Now (Motley Fool)
Dec-12-24 05:51AM	The Ultimate Biotech Stock to Buy With $500 Right Now (Motley Fool)
Dec-10-24 05:50PM	Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Dec-09-24 01:23PM	Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock (Benzinga)
05:50AM	2 No-Brainer Stocks to Buy Before the End of 2024 (Motley Fool)
04:00AM	Loading…
04:00AM	Gene therapy uptake in sickle cell stays slow, despite patient interest (BioPharma Dive)
Dec-08-24 12:52PM	Vertex Presents Positive Long-Term Data On CASGEVY (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update (Business Wire)
Dec-07-24 06:46AM	3 No-Brainer Growth Stocks to Buy in December (Motley Fool)
Dec-05-24 07:15AM	Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? (Motley Fool)
05:27AM	3 of the Best Growth Stocks You Can Buy for Less than $100 (Motley Fool)
Dec-04-24 11:30AM	Why Is Vertex (VRTX) Down 8.6% Since Last Earnings Report? (Zacks)
09:00AM	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (Zacks)
Nov-30-24 04:35AM	Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65% (Motley Fool)
Nov-28-24 05:50AM	Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. (Motley Fool)
Nov-24-24 05:47AM	Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? (Motley Fool)
Nov-23-24 06:30AM	3 Monster Stocks in the Making (Motley Fool)
Nov-22-24 06:10AM	Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock (Insider Monkey)
05:51AM	Got $500? 1 Biotech Stock to Buy and Hold Forever (Motley Fool)
Nov-19-24 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Nov-18-24 06:03AM	3 Growth Stocks You Can Buy Right Now Without Any Hesitation (Motley Fool)
Nov-14-24 12:27PM	Stock Market Today: Chevron Breaks Out, But Biotechs Struggle As Eli Lilly Looks Like Short-Sale Play (Live Coverage) (Investor's Business Daily)
Nov-13-24 04:15AM	Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity (Motley Fool)
Nov-09-24 08:00AM	Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points (Investor's Business Daily)
08:00AM	Five S&P 500 Stocks On This Elite IBD List Near Buy Points (Investor's Business Daily)
Nov-08-24 05:10PM	Stock Market: Three Top Names In Buy Zones, One With Earnings Due (Investor's Business Daily)
10:00AM	2 Biotech Stocks You Can Buy Hand Over Fist This Month (Motley Fool)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Nov-06-24 09:35AM	Vertex Pharmaceuticals (VRTX) Just Overtook the 20-Day Moving Average (Zacks)
09:30AM	Vertex Pharmaceuticals (VRTX) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
05:00AM	Moderna said to shuffle sales leadership; Vertex records first Casgevy sale (BioPharma Dive)
12:00AM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
Nov-05-24 06:30PM	Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +5.73%
04:08PM	Vertex Flashes A Surprise Buy Point As Non-Opioid Pain Drug Looms (Investor's Business Daily)
01:27PM	Vertex shares up after full-year product revenue guidance boost (Pharmaceutical Technology)
10:05AM	Vertex Gears Up For Its Next 'Leg Of Stock Upside' With Its Non-Opioid Pain Drug (Investor's Business Daily)
09:32AM	5 Top Stocks to Buy in November (Motley Fool)
07:40AM	Q3 2024 Vertex Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
05:53AM	My 2 Favorite Growth Stocks to Buy Hand Over Fist in November (Motley Fool)
02:06AM	Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-24 08:45PM	Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript (Motley Fool)
05:20PM	Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' (Investor's Business Daily)
05:15PM	Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:25PM	Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms (Investor's Business Daily)
04:10PM	Vertex: Q3 Earnings Snapshot (Associated Press Finance)
04:04PM	Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength (Reuters)
04:01PM	Vertex Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-03-24 07:00AM	What To Expect in the Markets This Week (Investopedia)
Oct-30-24 05:50PM	Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today (Zacks)
Oct-29-24 04:05PM	Vertex to Participate in Upcoming November Investor Conferences (Business Wire)
Oct-28-24 06:00PM	Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
10:01AM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-26-24 06:32AM	The Ultimate Biotech Stock to Buy With $50 Right Now (Motley Fool)
Oct-25-24 01:00PM	Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress (Business Wire)
05:45AM	The Smartest Growth Stock to Buy With $500 Right Now (Motley Fool)
Oct-24-24 09:15AM	Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits (Motley Fool)
Oct-22-24 09:00AM	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (Zacks)
Oct-21-24 06:00PM	Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today (Zacks)
Oct-19-24 09:15AM	Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030 (Motley Fool)
Oct-18-24 08:00AM	Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting (Business Wire)
Oct-14-24 06:00PM	Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
Oct-13-24 09:00AM	Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever (Motley Fool)
07:15AM	3 No-Brainer Growth Stocks to Buy in October (Motley Fool)
05:40AM	What is the US election impact on the Biotech sector (Investing.com)
Oct-10-24 04:05PM	Vertex to Announce Third Quarter 2024 Financial Results on November 4th (Business Wire)
Oct-09-24 03:50PM	Vertex Pharmaceuticals Inc (VRTX) Q2 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com)
10:15AM	2 Biotech Stocks to Buy Hand Over Fist in October (Motley Fool)
09:00AM	Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock (Zacks)
07:56AM	Is Vertex Pharmaceuticals Incorporated (VRTX) Positioned for Continued Success in Cystic Fibrosis and Beyond? (Insider Monkey)
Oct-07-24 06:00PM	Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Oct-04-24 05:17AM	3 Top Stocks That Could Still Rocket Higher in 2024 (Motley Fool)
04:45AM	2 Superior Growth Stocks That Are Screaming Buys Right Now (Motley Fool)
Oct-03-24 10:27AM	Reasons that Lifted Vertex Pharmaceuticals Incorporated (VRTX) in Q2 (Insider Monkey)
Oct-01-24 05:00AM	5 FDA decisions to watch in the fourth quarter (BioPharma Dive)
Sep-30-24 06:00PM	Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Sep-27-24 07:31AM	Vertex Pharmaceuticals presents vanzacaftor/tezacaftor/deutivacaftor data (TipRanks)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ALTSHULER DAVID	EVP, Chief Scientific Officer	Nov 15 '24	Sale	478.56	15	7,178	25,813	Nov 19 04:08 PM
ALTSHULER DAVID	Officer	Nov 15 '24	Proposed Sale	478.56	15	7,178		Nov 15 10:31 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Nov 11 '24	Sale	518.27	3,000	1,554,810	44,137	Nov 13 04:15 PM
Kewalramani Reshma	CEO & President	Nov 08 '24	Sale	515.00	15,198	7,826,970	75,772	Nov 12 04:08 PM
Kewalramani Reshma	Officer	Nov 08 '24	Proposed Sale	515.00	15,198	7,826,970		Nov 08 02:58 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02 '24	Sale	461.66	999	461,198	16,651	Oct 03 04:12 PM
Biller Jonathan	Officer	Oct 02 '24	Proposed Sale	461.66	999	461,198		Oct 02 10:04 AM
LEIDEN JEFFREY M	Executive Chairman	Aug 30 '24	Sale	499.00	3,784	1,888,216	9,994	Sep 04 04:13 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Option Exercise	152.74	646	98,670	5,081	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Sale	500.00	646	323,000	4,435	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Proposed Sale	500.00	646	323,000		Aug 30 04:47 PM
JEFFREY LEIDEN	Director	Aug 30 '24	Proposed Sale	493.35	3,784	1,866,836		Aug 30 04:23 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Option Exercise	152.74	1,292	197,340	5,727	Aug 12 04:08 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Sale	466.29	1,292	602,447	4,435	Aug 12 04:08 PM
Bozic Carmen	EVP and CMO	Aug 07 '24	Sale	476.75	2,280	1,086,990	23,259	Aug 08 04:06 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Proposed Sale	466.29	1,292	602,447		Aug 08 11:47 AM
Bozic Carmen	Officer	Aug 07 '24	Proposed Sale	476.75	2,280	1,086,990		Aug 07 09:52 AM
SACHS BRUCE I	Director	Aug 01 '24	Option Exercise	125.71	5,295	665,634	45,295	Aug 02 04:10 PM
SACHS BRUCE I	Director	Aug 01 '24	Sale	508.00	5,295	2,689,860	40,000	Aug 02 04:10 PM
Kewalramani Reshma	CEO & President	Jul 30 '24	Sale	505.00	15,202	7,677,010	90,970	Aug 01 04:17 PM
SACHS BRUCE I	Director	Aug 01 '24	Proposed Sale	508.00	5,295	2,689,860		Aug 01 03:34 PM
Kewalramani Reshma	Officer	Jul 30 '24	Proposed Sale	505.00	15,202	7,677,010		Jul 30 03:25 PM
Bozic Carmen	EVP and CMO	Jul 24 '24	Sale	488.46	2,280	1,113,689	25,539	Jul 25 04:06 PM
Kewalramani Reshma	CEO & President	Jul 22 '24	Sale	497.00	15,202	7,555,394	106,172	Jul 24 04:05 PM
Bozic Carmen	EVP and CMO	Jul 10 '24	Sale	487.34	2,280	1,111,135	27,819	Jul 12 04:07 PM
Bozic Carmen	EVP and CMO	Jun 26 '24	Sale	471.72	2,280	1,075,522	30,099	Jun 28 04:04 PM
Bozic Carmen	EVP and CMO	Jun 12 '24	Sale	478.00	2,280	1,089,840	32,379	Jun 13 04:11 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Jun 12 '24	Sale	478.00	7,288	3,483,664	15,972	Jun 13 04:09 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jun 03 '24	Sale	460.00	3,250	1,495,000	47,137	Jun 05 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Jun 03 '24	Sale	460.00	2,175	1,000,500	49,098	Jun 05 04:08 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 30 '24	Sale	439.11	2,350	1,031,908	53,523	Jun 03 04:09 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 31 '24	Sale	445.00	2,250	1,001,250	51,273	Jun 03 04:09 PM
Bozic Carmen	EVP and CMO	May 29 '24	Sale	445.56	2,280	1,015,877	34,659	May 31 04:19 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	May 28 '24	Sale	454.79	3,250	1,478,068	50,387	May 30 04:07 PM
Kewalramani Reshma	CEO & President	May 24 '24	Option Exercise	187.53	1,565	293,484	122,939	May 29 04:08 PM
Kewalramani Reshma	CEO & President	May 24 '24	Sale	457.00	1,565	715,205	121,374	May 29 04:08 PM
SACHS BRUCE I	Director	May 22 '24	Option Exercise	93.51	7,073	661,396	47,073	May 24 04:13 PM
SACHS BRUCE I	Director	May 22 '24	Sale	448.00	7,073	3,168,704	40,000	May 24 04:13 PM
Kewalramani Reshma	CEO & President	May 20 '24	Sale	447.00	15,202	6,795,294	121,374	May 22 04:21 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	May 15 '24	Sale	430.93	32	13,790	55,325	May 17 04:27 PM
Arbuckle Stuart A	EVP, COO	May 15 '24	Sale	430.93	69	29,734	49,691	May 17 04:24 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	May 15 '24	Sale	430.93	54	23,270	25,813	May 17 04:22 PM
Bhatia Sangeeta N.	Director	May 02 '24	Sale	402.95	467	188,178	4,435	May 03 04:05 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Apr 02 '24	Sale	419.00	240	100,560	7,500	Apr 03 04:02 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 26 '24	Sale	425.70	354	150,698	55,804	Feb 27 05:02 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 26 '24	Sale	425.70	3,004	1,278,803	55,325	Feb 27 04:59 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 26 '24	Sale	425.70	883	375,893	15,972	Feb 27 04:44 PM
Arbuckle Stuart A	EVP, COO	Feb 26 '24	Sale	425.70	5,034	2,142,974	49,691	Feb 27 04:37 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 26 '24	Sale	425.70	883	375,893	7,965	Feb 27 04:29 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 26 '24	Sale	425.70	4,239	1,804,542	25,813	Feb 27 04:24 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 21 '24	Sale	421.77	360	151,837	59,467	Feb 23 04:28 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 21 '24	Sale	421.77	3,191	1,345,868	60,798	Feb 23 04:20 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 21 '24	Sale	421.77	1,201	506,546	18,509	Feb 23 04:16 PM
Arbuckle Stuart A	EVP, COO	Feb 21 '24	Sale	421.77	3,603	1,519,637	59,439	Feb 23 04:12 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 21 '24	Sale	421.77	3,002	1,266,154	34,022	Feb 23 04:10 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 20 '24	Sale	420.79	480	201,979	59,827	Feb 21 04:43 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 20 '24	Sale	420.79	4,254	1,790,041	63,989	Feb 21 04:38 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 20 '24	Sale	420.79	801	337,053	19,710	Feb 21 04:23 PM
Arbuckle Stuart A	EVP, COO	Feb 20 '24	Sale	420.79	4,804	2,021,475	63,042	Feb 21 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 20 '24	Sale	420.79	4,002	1,684,002	37,024	Feb 21 04:13 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 15 '24	Sale	419.16	4,655	1,951,190	17,896	Feb 16 04:07 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 14 '24	Sale	419.04	4,356	1,825,338	22,551	Feb 16 04:07 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 12 '24	Sale	419.51	2,656	1,114,205	27,644	Feb 14 04:04 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 13 '24	Sale	419.13	737	308,899	26,907	Feb 14 04:04 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 12 '24	Sale	420.24	3,222	1,354,013	74,364	Feb 13 05:15 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 12 '24	Sale	418.77	1,738	727,822	18,280	Feb 13 04:56 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 12 '24	Sale	420.24	913	383,679	23,137	Feb 13 04:54 PM
Arbuckle Stuart A	EVP, COO	Feb 12 '24	Sale	420.24	4,295	1,804,931	75,718	Feb 13 04:51 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 12 '24	Sale	420.24	1,374	577,410	9,676	Feb 13 04:48 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 12 '24	Sale	420.24	3,145	1,321,655	47,588	Feb 13 04:46 PM
LEIDEN JEFFREY M	Executive Chairman	Jan 08 '24	Sale	419.07	6,648	2,785,977	2,423	Jan 10 04:06 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jan 02 '24	Sale	405.00	3,000	1,215,000	43,693	Jan 04 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRTX

Vertex Pharmaceuticals, Inc

Upgrade your FINVIZ experience